Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy

Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy

Paweł Rubiś, Sylwia Wiśniowska‑Śmiałek, Katarzyna Holcman, Agata Leśniak‑Sobelga, Magdalena Kostkiewicz, Piotr Podolec

DOI: 10.20452/pamw.3982

Published online: March 21, 2017
CC BY-NC-SA 4.0

Full-text article available only as a pdf file for download

Download PDF

Most cited

Lippi G, Wong J, Henry B

Pol Arch Intern Med. 2020, Vol. 130, No. 4: 304–309; DOI: 10.20452/pamw.15272

Staszel T, Zapała B, Polus A, Sadakierska‑Chudy A, Kieć‑Wilk B, Stępień E, Wybrańska I, Chojnacka M, Dembińska‑Kieć A

Pol Arch Intern Med. 2011, Vol. 121, No. 10: 361–367; DOI: 10.20452/pamw.1093

Kasińska M, Drzewoski J

Pol Arch Intern Med. 2015, Vol. 125, No. 11: 803–813; DOI: 10.20452/pamw.3156

Chou R

Pol Arch Intern Med. 2009, Vol. 119, No. 7-8: 469–477; DOI: 10.20452/pamw.741

Edrees H, Paine L, Feroli E, Wu A

Pol Arch Intern Med. 2011, Vol. 121, No. 4: 101–108; DOI: 10.20452/pamw.1033

Lippi G, Sanchis-Gomar F, Henry B

Pol Arch Intern Med. 2023, Vol. 133, No. 4: 16402; DOI: 10.20452/pamw.16402

Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, Bai X, Ding M, Liu W, Liu K, Chu Y

Pol Arch Intern Med. 2020, Vol. 130, No. 5: 390–399; DOI: 10.20452/pamw.15312